BEGIN:VCALENDAR
PRODID:-//planitpurple.northwestern.edu//iCalendar Event//EN
VERSION:2.0
CALSCALE:GREGORIAN
METHOD:PUBLISH
CLASS:PUBLIC
BEGIN:VTIMEZONE
TZID:America/Chicago
TZURL:http://tzurl.org/zoneinfo-outlook/America/Chicago
X-LIC-LOCATION:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:19700308T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:19701101T020000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
SEQUENCE:0
DTSTART;TZID=America/Chicago:20251218T100000
DTEND;TZID=America/Chicago:20251218T110000
DTSTAMP:20260717T090725Z
SUMMARY:BMG Seminar: Lindsay Pino\, PhD\, Talus Bio
UID:636061@northwestern.edu
TZID:America/Chicago
DESCRIPTION:The Department of Biochemistry & Molecular Genetics presents:  Lindsay Pino\, PhD Co-founder and Chief Technology Officer Talus Bioscience\, Inc.  Presentation:   Profiling the regulome with high-throughput proteomics to enable small-molecule therapeutics  Abstract:  Transcription factors\, cofactors\, and chromatin regulators orchestrate gene expression yet remain poorly measured in their native chromatin context and historically difficult to drug. To address these challenges\, we developed regulome profiling\, a functional proteomics approach that quantifies protein–DNA binding activity in live cells using high-throughput mass spectrometry. This assay measures regulator activity directly\, generating proteome-wide maps of DNA engagement that can be compared across perturbations\, cell types\, and chemical treatments.  Because of its flexibility and high-dimensional output\, regulome profiling delivers actionable biological insight across diverse contexts. In deorphanization\, we uncover off-target DNA-binding effects of anthracyclines\, uncovering new mechanisms of action not previously associated with this drug class. In toxicity studies\, regulome signatures reveal early regulatory disruptions preceding transcriptomic or phenotypic changes. In drug discovery\, these activity maps expose tractable intervention points directly within disease-relevant cell contexts\, seeding a pipeline of small-molecule therapeutics against transcription factors including brachyury (TBXT) and androgen receptor variants.  To accelerate these drug discovery efforts\, we built an AI model on top of this unique data\, called Strategian. Strategian triages billions of compounds by predicted impact on transcription-factor activity and selectivity\, feeding prioritized candidates back into regulome profiling for experimental validation. This closed-loop\, two-week iteration connects small-molecule chemistry to chromatin regulatory biology\, transforming transcriptional control into a measurable and druggable system.  Host: Dr. Ali Shilatifard\, Chairman\, Biochemistry and Molecular Genetics; Director\, Simpson Querrey Institute for Epigenetics  Refreshments will be served.
LOCATION:Robert H Lurie Medical Research Center\, Baldwin Auditorium\, 303 E. Superior\, Chicago\, IL 60611
TRANSP:OPAQUE
URL:https://planitpurple.northwestern.edu/event/636061
CREATED:20220725T050000Z
STATUS:CONFIRMED
LAST-MODIFIED:20251117T232200Z
PRIORITY:0
BEGIN:VALARM
TRIGGER:-PT10M
ACTION:DISPLAY
DESCRIPTION:Reminder
END:VALARM
END:VEVENT
END:VCALENDAR